A statistical method for estimating the no-observed-adverse-event-level

Publikation: Arbeitspapier/Preprint › Preprint

Autoren

  • Ludwig A. Hothorn

Organisationseinheiten

Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
PublikationsstatusElektronisch veröffentlicht (E-Pub) - 2 Jan. 2021

Abstract

In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

Zitieren

A statistical method for estimating the no-observed-adverse-event-level. / Hothorn, Ludwig A.
2021.

Publikation: Arbeitspapier/Preprint › Preprint

Download
@techreport{be25acf6b4b54823bf436ab2c1ab321b,
title = "A statistical method for estimating the no-observed-adverse-event-level",
abstract = " In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays. ",
keywords = "stat.AP",
author = "Hothorn, {Ludwig A.}",
note = "4 data examples, with raw data and R-code",
year = "2021",
month = jan,
day = "2",
language = "English",
type = "WorkingPaper",

}

Download

TY - UNPB

T1 - A statistical method for estimating the no-observed-adverse-event-level

AU - Hothorn, Ludwig A.

N1 - 4 data examples, with raw data and R-code

PY - 2021/1/2

Y1 - 2021/1/2

N2 - In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

AB - In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

KW - stat.AP

M3 - Preprint

BT - A statistical method for estimating the no-observed-adverse-event-level

ER -